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OBJECTIVE: The objective of this selective EBM review is to determine whether or not 
vitamin D is an effective treatment method in reducing mortality due to cardiovascular disease. 
 
STUDY DESIGN: A review of two double blind, randomized controlled trials (RCTs) and one 
randomized open-label study published in the English language after 2008. The articles 
compared oral, intramuscular, or oil drops of vitamin D to a placebo group.  
 
DATA SOURCES: One double-blind randomized controlled trial, one randomized control trial 
that was not blinded, and one randomized open-label study were found using PubMed, Medline, 
Embase, or Cochrane. The articles were selected based on their correlation to the specified topic, 
date of publications, and their evaluation of POEMs. 
 
OUTCOMES MEASURED: The effect of vitamin D supplementation on reducing mortality in 
patients with cardiovascular disease will be measured. Mortality was measured by main cause of 
death from death registrations, Rankin scales, repeated contacts with the participants, contact 
with family physicians, regular review of medical records, and consultation of the respective 
registration office. 
 
RESULTS: Two studies used in this review showed no significant improvement in vitamin D 
allocation in the reduction of mortality due to cardiovascular disease while one found clinical 
significance in the allocation of vitamin D. Avenell et al. and Zittermann et al.’s studies were not 
able to demonstrate an improvement in vascular mortality or all-cause mortality respectively 
with vitamin D supplementation. Gupta et al. reported a potential benefit in ischemic stroke 
survivors with vitamin D insufficiency or deficiency with the supplementation of vitamin D and 
calcium. This is the only RCT that did not separate calcium and vitamin D supplementation and 
instead combined both which showed a trend towards reduction in mortality.  
 
CONCLUSIONS: The results of these studies showed no significant improvement in vitamin D 
allocation alone to reducing cardiovascular death. Although Gupta et al. reported a statistically 
significant lower mortality rate in the treatment arm compared to the placebo, it did not separate 
vitamin D allocation from calcium therefore we cannot assume that vitamin D supplementation 
alone reduced death from cardiovascular disease. Future studies should be conducted when 
vitamin D supplementation is given before a major cardiovascular event such as a stroke or heart 
failure. 
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INTRODUCTION 
Cardiovascular disease (CVD) is a broad term that encompasses different types of 
diseases. CVD can include diseases such as: hypertension; coronary heart disease, including 
myocardial infarction, angina pectoris, and heart failure; cerebrovascular disease, including 
stroke and transient ischemic attack; peripheral artery disease including intermittent claudication; 
and aortic atherosclerosis and thoracic or abdominal aortic aneurysm. Heart disease is the leading 
cause of death for both women and men a year, accounting for about 1 in 4 deaths, and with 
about 610,000 people dying of heart disease in the United States every.1,2 The incidence of CVD 
continues to increase as the five leading modifiable risk factors (hypercholesterolemia, diabetes, 
hypertension, obesity, and smoking) continue to be major risk factors in today’s society.2 It is 
estimated that these risk factors are responsible for more than half of cardiovascular mortality. 
Lifetime risk of overall cardiovascular heart disease has begun to approach 50 percent for 
persons age 30 years and up with no known cardiovascular disease.1 In 2016, cardiovascular 
disease cost America $555 billion. By 2035, the cost is estimated to skyrocket to $1.1 trillion.3 
According to the CDC, 6.7% of office-based physician visits were for coronary artery 
disease, ischemic heart disease, or history of myocardial infarction.2 Five and nine tenths percent 
of visits to the emergency departments included a diagnosis of coronary artery disease, ischemic 
heart disease, or myocardial infarction.2  
Cardiovascular disease is caused by underlying atherosclerosis. The dysfunction of the 
endothelial layer is thought to be the initial step in atherosclerosis and is thought to be caused by 
loss of endothelium-derived nitric oxide which can cause a loss of vasodilation of the vessels.   
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Inflammation is also a crucial step of the buildup of atherosclerosis in which 
macrophages that have been taken up by oxidized LDL, also known as “foam cells,” release 
inflammatory factors including growth factors, cytokines, and other inflammatory substances. 
These inflammatory factors can act on smooth muscle cells and other pro-inflammatory 
cytokines to induce cell proliferation. Intracellular lipids, extracellular deposits and T 
lymphocytes accumulate early within the intimal layer of the blood vessel forming a fatty streak. 
As the fatty streak begins to expand, smooth muscle cells accumulate in the intima. As the 
smooth muscle cells undergo apoptosis within the fatty streak, this begins to increase the amount 
of macrophage accumulation and micro-vesicles that can calcify and in turn leading to the 
formation of atherosclerotic plaques.1 As aging takes place, the lesions begin to progress to 
plaques in early adulthood and accumulate to thrombotic occlusion acute cardiovascular events 
in middle age and later adulthood.  
Cardiovascular disease of different origins can present in patients in many different 
aspects. Generalized symptoms for cardiovascular disease can include chest pain and tightness, 
shortness of breath, pain and numbness in distal extremities, lightheadedness, irregular 
heartbeats, dizziness, edema in the hands, ankles, or feet, and headaches. Although 
cardiovascular disease continues to be prevalent in today’s society, there are many non-
pharmaceutical and pharmaceutical methods that could assist with the management of 
cardiovascular disease. Lifestyle and diet modifications such as exercising regularly, smoking 
cessation, and decreasing fatty and processed foods intake with an increase in fruits and 
vegetables are the initial steps in management. Pharmacological agents such as diuretics, ACE 
inhibitors, angiotensin II receptor blockers, calcium channel blockers, beta blockers, and statin 
therapy can all assist in managing cardiovascular disease.1 Currently, there is no definitive cure   
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for cardiovascular disease however the medications listed as well as lifestyle modifications and 
controlling underlying conditions have improved symptoms in individuals with cardiovascular 
disease. Vitamin D may assist in reducing mortality among these patients although many 
systematic reviews have not been done to prove any correlation. Vitamin D is able to decrease 
prostaglandins, COX-2, and pro-inflammatory cytokines to reduce inflammation       
decrease calcium cellular influx while increasing matrix Gla protein, which inhibits vascular 
calcification and smooth muscle proliferation. It is also able to decrease renin in turn regulating 
blood pressure and volume homeostasis.8 Reduction in the formation of atherosclerotic plaques 
and smooth muscle proliferation leading to endothelial damage can lead to a decrease in all 
forms of cardiovascular disease. More recent studies have been investigating if vitamin D 
supplementation may be used as an oral, intramuscular (IM), or in the form of oil drops 
supplementation to decrease morbidity and mortality associated with cardiovascular disease. 
OBJECTIVE 
The objective of this selective EBM review is to determine whether or not vitamin D is 
an effective treatment method in reducing mortality in patients who have cardiovascular disease. 
METHODS 
 All three articles were researched using PubMed, Medline, Embase, or Cochrane and 
were chosen based on their clinical relevance to the research question and their patient-oriented 
outcomes. The key words used to research these articles included “vitamin D”, “cardiovascular 
diseases”, and “mortality.” All of the articles included in this review are published in the English 
language after 2008. Inclusion criteria included human studies that were randomized and  
controlled, in the English language, and on the subject of humans while studies published more 
than 10 years ago and articles on other species were excluded. The summary of statistics 
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included numbers needed to treat (NNT), RBI, CER, EER, ABI, and P-values. Three randomized 
controlled trial studies on the use of vitamin D supplementation (orally, IM, or oil drops) on 
adults aged 18 and over with ischemic stroke, fractures, vascular diseases, and heart failure were 
studied in this analysis (Table 1). All three trials compared a treatment group receiving vitamin 
D supplementation to the experimental group who received no vitamin D supplementation or 
usual care for their underlying disease. The outcomes of these articles focused on decrease in 
mortality in cardiovascular disease patients with vitamin D supplementation. The results were 
measured by main cause of death from death registrations, Rankin scales, repeated contacts with 
the participants, contact with family physicians, regular review of medical records, and 
consultation of the respective registration office. 
OUTCOMES MEASURED 
 The outcomes that were measured were based on a Patient Oriented Evidence that 
Matters (POEM). This EBM review measured the effect of vitamin D supplementation on 
reducing mortality in patients with cardiovascular disease. 
      Avenell et al. used vascular disease mortality from data that was derived only from main 
cause of death from death registrations that were collected through the national United Kingdom 
databases of the General Register of Scotland and the National Health Service Medical Research 
Information Service.5 Zitterman et al. tested for all-cause mortality as well, which was measured 
by repeated contacts with the participants, contact with family physicians, regular review of 
medical records, and consultation of the respective registration office.6 Gupta et al. used the 
Modified Rankin scale Scale (mRS) at 3 months and 6 months post stroke.7 The mRS  
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Table 1. Demographics and Characteristics of Included Studies 
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measures the degree of dependence or disability in the daily activities of people who have 
suffered a stroke or other causes of neurological disability. For this systematic review, the  
Modified Rankin scale score of 6 was used as a validating measure signifying death in these 
stroke patients.  
RESULTS 
 This review included 3 randomized control trials to assess the effect of vitamin D 
supplementation on cardiovascular mortality. The inclusion and exclusion criteria for all three 
trials can be found in Table 1 above.  
Avenell et. al selected 5,292 people with a mean age of 77 of whom 2,649 received 
vitamin D3 supplementation and 2,643 were in the control group. Majority of the candidates in 
the vitamin D and placebo groups had similar descriptions including being Caucasian female, 
32% having a high risk for vitamin D deficiency, 12% being smokers, and equal percentages 
having proximal femur, leg and pelvic or distal forearm fractures. Randomization was computer 
generated, assigned into groups and minimized by age.5  
Participants were randomized into 2 groups with one group receiving two tablets daily 
with meals containing a total of 800 IU vitamin D3 and one receiving the placebo.  The study 
reported follow-up mortality data that had been notified through the trial and the 3-year follow-
up period.  During the trial and 3 years of follow-up, it was found that 32.4% (1,717) of the 
5,292 died with the main cause of death being vascular disease for 42.3% (726) of the 1,717 
participants. Vitamin D supplementation showed to only slightly reduce vascular death as 836 
participants (31.6%) of the 2,649 participants allocated vitamin D died, compared with the 881 
of the 2,643 (33.3%) participants not allocated vitamin D dying from vascular causes. The 
reduction in mortality showed a confidence interval between 0.79 and 1.05 for the comparison of 
  Pendleton, Vitamin D for CVD 
   
 
vitamin D administration vs. placebo in vascular death specifically with a p-value of 0.175. This 
indicated there was not a statistically significant difference shown by a treatment effect with a 
wide and imprecise confidence interval. The NNT calculated in this study was 100 making the 
treatment effect very large. Table 2 of this review shows the CER, EER, RBI, ABI, and NNT 
values. Compliance proved to be an issue in the study in which those returning questionnaires 
showed the rate of pill takers had decreased to 67% at 12 months and 63% at 24 months.4 No 
adverse health effects were noted in this RCT.  
Table 2. Rate of Death Due to Vascular Disease in Placebo vs. Treatment Arms 
CER EER RBI ABI NNT 
0.142 0.132 -0.0704 0.01 100 
Note: CER= Control Event Rate; EER= Experimental Event Rate; RBI= Relative Benefit 
Increase; ABI= Absolute Benefit Increase; NNT= Numbers Needed to Treat 
 
The double-blind randomized control study conducted by Zittermann et al. included 
patients 18-79 years old that were classified as having New York Heart Association functional 
class II or higher. These candidates were either listed as “elective” for heart transplantation or 
were in a long-term program for heart transplantation. Of the 400 randomized candidates, 199 
were allocated to receive 4000 IU vitamin D3 daily in the form of eight drops of an oily vitamin 
D preparation known as Vigantol oil.6 The 201 candidates that were randomized to receive  
placebo received a matching vitamin D- free oil daily (Migliol oil) during a meal. Concealment 
in both parties was achieved by sequentially numbered drug containers.  
Eighty-five candidates of the treatment arm and 84 candidates of the placebo arm  
discontinued intervention due to center transfer, poor health condition, no pleasure to participate, 
hypercalcemia, home-based care, and “other reasons.”6 Majority of the patients selected in the 
study included males who suffered from dilated or ischemic cardiomyopathy with 80% having a 
pacemaker and 41% having a baseline 25(OH)D level. The hazard ratio for the vitamin D
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versus placebo group was 1.09, which signifies a very slight difference in survival between the 
two groups. The p-value found was 0.726 which proved to be statistically insignificant. Table 3 
shows the change in all-cause mortality noted in both the placebo and vitamin D arms. 
Table 3. Comparison in All-Cause Mortality in Vitamin D vs. Placebo6 





199 194 188 180 174 166 166 19.6% 
Placebo  201 194 185 180 174 166 160 17.9% 
   
Gupta et al. conducted a randomized controlled open-label trial at a tertiary hospital that 
included 53 patients that were equal or over the age of 35 of who presented within 7 days of 
onset of first ever ischemic stroke and a pre-stroke modified Rankin score of less than 2. 
Randomization was done by a random number generator on the computer. While the control 
group received “usual post-stroke care alone,” which was not specified in the article, the 
intervention group received a single intramuscular injection of 600,000 IU cholecalciferol 
followed by 60,000 IU of oral cholecalciferol once a month with one-gram elemental calcium 
daily along with usual poststroke care.7  
Of the 53 randomized candidates, all of the candidates had a baseline vitamin D level less 
than 75 nmol/L. The intervention arm began with 25 candidates while 4 were lost to follow-up 
by 6 months. In comparison, the usual care arm began with 28 candidates while 5 were lost to 
follow-up by 6 months. By 6 months, the intervention group had a total of 4 deaths as opposed to 
11 total deaths in the usual post-stroke care alone group. Gupta et al. used an intention to treat 
basis at the final follow-up with 11 patients (44%) having a “good outcome”, classified as a 
modified Rankin score of 0-28, in the intervention arm; while 11 patients (39.3%) had a good 
outcome in the usual care arm. The outcome analysis showed a decrease in mortality with 
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vitamin D and calcium showed by Table 3. No adverse health effects were noted in this study 
that directly correlated with vitamin D administration alone. Low calcium levels that were said to 
be caused by vitamin D deficiency stimulated an excessive amount of parathyroid hormone 
releasing resulting in a secondary hyperparathyroidism.7  
Table 4. Outcome Comparisons in the Vitamin D plus Calcium Group vs. Treatment by Usual 
Care Alone Group7 
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The results from Avenell et al.’s study was not able to demonstrate an improvement in 
vascular mortality with vitamin D supplementation. Although, Avenell et al.’s experimental 
group proved to be the largest of the RCTs, the population was limited to Caucasian females 
with a mean age of 77 who had a previous fracture 3 months or longer from enrollment. 
Although there was no significant reduction in the mortality of the specified population used, 
Avenell et al. stated that it is not known if these results would apply in younger people, older 
people without a history of a fragility fracture, or high-risk populations in nursing homes. Other 
limitations included variation in size and shape of the vitamin D and placebo tablets and lack of 
concealment as a part of randomization in the trial which could lead to lack of validity in the 
trial. On the other hand, Zittermann et al. had a strong representation of middle-aged males with 
New York Heart Association Functional Class II heart failure. However, Zittermann et al. admits 
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that enrollment did not reach the planned number of study participants and the annual mortality 
was lower than originally expected therefore showing a low statistical power to assess an actual 
significant difference between the experimental arm and placebo.5 Although both studies’ results 
met the requirement for this systematic review, the specificity of each studies’ population could 
be accounted as a limitation in both studies. 
Gupta et al. reported a potential benefit in ischemic stroke survivors with vitamin D 
insufficiency or deficiency with the supplementation of vitamin D and calcium. This is the only 
RCT that did not separate calcium and vitamin D supplementation and instead combined both 
which showed a trend towards improvement in disability. However, it is noted in the study that 
the baseline differences in serum cholesterol because the supplemental arm had higher baseline 
levels, dietary habits and level of outdoor physical activity, and prevalence of atherosclerosis, 
which was not evaluated in detail in the study, were not considered and cannot be ruled out when 
discussing trends towards disability in this article specifically. The randomization and allocation 
were done by a single investigator and was not blinded which could have led to bias or other 
study limitations.  
The National Institute of Health recommended dietary allowances of vitamin D to be 600 
IU in males and females aged 14-70 years old and 800 IU in males and females over the age of 
70. Although rare, vitamin D toxicity can to hypercalcemia and other non-specific signs such as 
weight loss, polyuria, anorexia, and heart arrhythmias.9 
CONCLUSION 
 Based on the results of this systematic review, there is no significant improvement in 
reducing mortality due to cardiovascular disease with vitamin D supplementation. Gupta et al. 
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showed a potential benefit of vitamin D supplementation along with calcium supplementation in 
reducing all-cause mortality in stroke victims.   
 Future studies should be conducted when vitamin D supplementation is given before a 
major cardiovascular event such as a stroke or heart failure. Vitamin D supplementation in early 
stages of cardiovascular disease such as hypertension should be studied to assess all cause-
mortality with vitamin D supplementation over years rather than short time durations. Future 
studies are warranted in a more diverse group of candidates and including ultraviolet light as a 
possible supplement with dietary, intramuscular, or oral vitamin D supplementation. The use of 
vitamin D early in cardiovascular disease can reduce cardiovascular complications and costs in 
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